Showing results (81-90 of 92) with videos related to
Sort By:
Pageof 10
Blood Advances|December 5, 2023
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaAndrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, et al.Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.Nature Communications|April 28, 2022
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cellsTianyu Cai, Agnès Gouble, Kathryn L Black, et al.The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.Blood Neoplasia|March 12, 2026
Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemiaYoke Seng Lee, Jonathan D Good, Noha Awais, et al.Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.Nature Genetics|April 22, 2014
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylationAndrew A Lane, Bjoern Chapuy, Charles Y Lin, et al.The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.Blood|November 18, 2022
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needNaveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, et al.Pageof 10